Gene Therapy: Industry Seeks Greater Clarity In Final FDA CMC Guidance On INDs
Industry asks the US FDA to refine the focus of draft guidance on the chemistry, manufacturing and controls information that should go into investigational new drug applications for gene therapies. Questions center on a scope that ranges from CTD to GMP, from in vivo to ex vivo, and from IND to BLA.
You may also be interested in...
New draft document addresses issues with applying quality-by-design to gene therapies, accommodating the Common Technical Document format, as well as drug substance, cell bank and contract manufacturing issues. US FDA's Denise Gavin offers insights on agency thinking at gene therapy conference.
Proposal could yield a bounty of new options for innovative drug delivery systems.
Data integrity issues were raised in many warning letters to active pharmaceutical ingredient manufacturers over the past four years.